These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18815560)

  • 1. Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
    Schran HF; Hager DF
    Pancreas; 2008 Oct; 37(3):334-5; author reply 336-7. PubMed ID: 18815560
    [No Abstract]   [Full Text] [Related]  

  • 2. Octreotide LAR in carcinoid: how to dose?
    Yao JC; Kvols LK
    Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients.
    Woltering EA; Salvo VA; O'Dorisio TM; Lyons J; Li G; Zhou Y; Seward JR; Go VL; Vinik AI; Mamikunian P; Mamikunian G
    Pancreas; 2008 Jul; 37(1):94-100. PubMed ID: 18580450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS; Khuroo MS; Khuroo NS
    J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
    Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
    Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
    Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors.
    Berković MC; Altabas V; Herman D; Hrabar D; Goldoni V; Vizner B; Zjacić-Rotkvić V
    Coll Antropol; 2007 Jun; 31(2):531-4. PubMed ID: 17847934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The treatment of carcinoid of the small intestine with octreotide and alpha-interferon. A call for participation in a randomized study].
    Ahrén B
    Dtsch Med Wochenschr; 1996 May; 121(22):744-5. PubMed ID: 8646989
    [No Abstract]   [Full Text] [Related]  

  • 10. Carcinoid and neuroendocrine tumors: building on success.
    Kunz PL
    J Clin Oncol; 2015 Jun; 33(16):1855-63. PubMed ID: 25918282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
    Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P
    Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carcinoid tumor and intravenous octreotide infusion during labor and delivery.
    Le BT; Bharadwaj S; Malinow AM
    Int J Obstet Anesth; 2009 Apr; 18(2):182-5. PubMed ID: 19200714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogranin A as a determinant of midgut carcinoid tumour volume.
    Kölby L; Bernhardt P; Swärd C; Johanson V; Ahlman H; Forssell-Aronsson E; Stridsberg M; Wängberg B; Nilsson O
    Regul Pept; 2004 Aug; 120(1-3):269-73. PubMed ID: 15177946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it time to widen the use of somatostatin analogs in neuroendocrine tumors?
    Oberg KE
    J Clin Oncol; 2009 Oct; 27(28):4635-6. PubMed ID: 19704053
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
    Anthony L; Vinik AI
    Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide scanning for carcinoid tumours.
    Critchley M
    Postgrad Med J; 1997 Jul; 73(861):399-402. PubMed ID: 9338023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum chromogranin A reflects regression of metastatic carcinoid during prolonged octreotide treatment.
    Pregun I; Gergics P; Dabasi G; Igaz P; Racz K; Tulassay Z
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):476-7. PubMed ID: 19382304
    [No Abstract]   [Full Text] [Related]  

  • 18. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
    Janson ET; Oberg K
    Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
    [No Abstract]   [Full Text] [Related]  

  • 19. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
    Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
    Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.